Recommendations for HER2 testing in the UK
Recommendations for HER2 testing in the UK
复制标题
DOI：
10.1136/jcp.53.12.890
复制
发表时间：
2000-12-01
影响因子：
3.4
通讯作者：
Lee, PB
中科院分区：
文献类型：
--
作者：
Ellis, IO;Dowsett, M;Lee, PB
确定乳腺癌的HER2状态是使用单克隆抗体曲妥珠单抗（Herceptin（R））的先决条件，曲妥珠单抗最近被许可用于治疗转移性疾病。这就需要根据档案材料进行测试。首选的分析是免疫组织化学与荧光原位杂交（FISH）作为一个后续的测试不明确的结果。已经制定了标准化的、控制良好的程序指南，以提供可靠的结果。已成立了一个由三个参考实验室组成的小组，在需要时提供咨询、质量保证和材料。
Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin(R)), which has recently been licensed for the treatment of metastatic disease. This necessitates a test based on archival material. The preferred analyses are immunohistochemistry with fluorescent in situ hybridisation (FISH) as a follow up test for ambiguous results. Guidelines have been developed for standardised, well controlled procedures for the provision of reliable results. A group of three reference laboratories has been established to provide advice, quality assurance, and materials, where needed.